About Storm Therapeutics
Storm Therapeutics is a clinical-stage biotechnology company that discovers and develops small-molecule therapies. It focuses on RNA-modifying enzymes to treat cancer and other diseases. Its lead product, STC-15, is an inhibitor of the RNA-modifying enzyme METTL3 and is being evaluated in clinical studies for various cancers.
Company Details
Corporate & Operational Profile
Web & Domain Identity
Social & Network Presence
Company Milestones & Timeline
- Capital Raise
Raised $56,000,000 · Series-B+
fundraisingfox.com
- Capital Raise
Raised $30,000,000 · Series-B+
- Capital Raise
Raised $16,063,200 · Series-A
- Milestone
X account created (@storm_tx)
974 followers
- Milestone
Website domain registered
stormtherapeutics.com
Investors & Backers
Funding History
Founders & Leadership
Atif Abbas
Chief Medical Officer
Eric Martin
Chief Development Officer
Eric Miska
Founder
Gerald McMahon
CEO and President
Marguerite Hutchinson
Chief Business Officer
Tony Kouzarides
Founder
Press Coverage & Sources
fundraisingfox.com/companies/storm-therapeutics
finsmes.com/2022/12/storm-therapeutics-closes-usd-30m-series-b-financing.html
m-ventures.com/en/news/archive-news/2016/storm-therapeutics-raises-12-million-series-a-funding-to-target-enzymes-that-modify-rna-to-generate-novel-cancer-therapeutics
Recently Funded Biotech & Healthcare Startups
View allVitalls
vitalls.ai
Hexagon Bio
hexagonbio.com
RefloDx
reflodx.com
HeyVoli
heyvoli.com
CureBay
curebay.com
4Tissue
4tissue.com